Jane Street Group LLC reduced its position in shares of CTI BioPharma Corp. (NASDAQ:CTIC) by 27.8% during the first quarter, Holdings Channel reports. The fund owned 55,393 shares of the biopharmaceutical company’s stock after selling 21,379 shares during the period. Jane Street Group LLC’s holdings in CTI BioPharma Corp. were worth $233,000 as of its most recent filing with the SEC.
Several other institutional investors have also made changes to their positions in the stock. Segantii Capital Management Ltd purchased a new stake in CTI BioPharma Corp. during the first quarter valued at about $102,000. Nine Chapters Capital Management LLC raised its stake in CTI BioPharma Corp. by 152.9% in the first quarter. Nine Chapters Capital Management LLC now owns 43,500 shares of the biopharmaceutical company’s stock valued at $183,000 after buying an additional 26,300 shares in the last quarter. Finally, Acadian Asset Management LLC purchased a new stake in CTI BioPharma Corp. during the first quarter valued at about $181,000. 23.71% of the stock is currently owned by institutional investors.
Shares of CTI BioPharma Corp. (NASDAQ CTIC) opened at 3.29 on Monday. The company’s 50 day moving average price is $3.75 and its 200 day moving average price is $3.87. The firm’s market capitalization is $92.27 million. CTI BioPharma Corp. has a 52-week low of $2.70 and a 52-week high of $6.48.
CTI BioPharma Corp. (NASDAQ:CTIC) last announced its quarterly earnings data on Wednesday, May 3rd. The biopharmaceutical company reported ($0.71) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.70) by $0.01. CTI BioPharma Corp. had a negative return on equity of 644.50% and a negative net margin of 346.56%. The firm had revenue of $0.75 million during the quarter. Analysts forecast that CTI BioPharma Corp. will post ($2.40) earnings per share for the current year.
CTI BioPharma Corp. Company Profile
CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL).
Want to see what other hedge funds are holding CTIC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CTI BioPharma Corp. (NASDAQ:CTIC).
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2284901/jane-street-group-llc-has-233000-position-in-cti-biopharma-corp-ctic.html
Receive News & Ratings for CTI BioPharma Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma Corp. and related companies with MarketBeat.com's FREE daily email newsletter.